Skip to main
TNGX

Tango Therapeutics (TNGX) Stock Forecast & Price Target

Tango Therapeutics (TNGX) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 55%
Buy 36%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

Tango Therapeutics is a promising biotechnology company focused on discovering and developing precision oncology therapies. The company is well positioned in the competitive PRMT5 inhibitor category with a compelling frontline registrational strategy in pancreatic cancer and potential development opportunities in other cancers such as non-small cell lung cancer. Upcoming data disclosures and expected initiations for clinical trials further support the company's positive outlook. The strong safety profile of vopimetostat, the company's leading PRMT5 inhibitor, will also differentiate it from other competitors in the market. However, there are potential risks such as R&D setbacks or regulatory delays that could impact the company's success and growth potential. Overall, the achievements and potential of Tango Therapeutics make it a promising investment opportunity with a bright future ahead.

Bears say

Tango Therapeutics is at a disadvantage in the competitive oncology market, with numerous competitors currently present and the constant threat of new drugs emerging. The company's pipeline products may face competition from other similar agents, especially from China, which could potentially reduce its revenues. The company also requires significant funding for its clinical trials, which may lead to potential ownership dilution for investors and carry risks through debt offerings. Additionally, the company's proposed collaborations with RevMed and ERASCA may not be enough to achieve success in the market, and an acquisition by a larger pharmaceutical company may be necessary for Tango to secure a larger upfront payment and secure an exclusive partnership.

Tango Therapeutics (TNGX) has been analyzed by 11 analysts, with a consensus rating of Buy. 55% of analysts recommend a Strong Buy, 36% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tango Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tango Therapeutics (TNGX) Forecast

Analysts have given Tango Therapeutics (TNGX) a Buy based on their latest research and market trends.

According to 11 analysts, Tango Therapeutics (TNGX) has a Buy consensus rating as of Sep 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tango Therapeutics (TNGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.